Immunotherapy for cat asthma

Metre, Thomas E. Van; Marsh, David G.; Adkinson, N. Franklin; Kagey‐Sobotka, Anne; Khattignavong, Arouna P.; Norman, Philip S.; Rosenberg, Gary L.

doi:10.1016/0091-6749(88)90144-3

Cited by 141 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In DBPC asthma studies assessing efficacy on bronchial challenge (BPT) or exposure tests (63,71) (Table 3), one grass-pollen study noted a reduction in BPT sensitivity (68), as was also the case for one out of three mite studies (65,70,71). Five studies have investigated the efficacy of cat and/or dog immunotherapy (63,64,66,67,69), and three documented a reduction in challenge test or improvement in exposure tests. A recently published study investigating the effectiveness of immunotherapy in children (72) was excluded from this review because mixtures of allergens were used.…”

Section: Clinical Efficacy In Asthmamentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

Section: Clinical Efficacy In Asthmamentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

“…Thus, when patients are subsequently exposed to the allergen, there are not sufficient amounts of specific IgE to sensitize mast cell/basophil FcεRI. In fact, a major anomaly exists as most studies find that immunotherapy does not reduce allergen-specific IgE levels [1,2,3,4,5,6], although mast cell/basophil-induced reactions are diminished [7,8,9]. Specifically, Creticos et al [1 ]showed that antigen-specific IgE levels do not decrease following allergy shots; instead antigen-specific IgE levels initially increase and do not fall below baseline/initial levels.…”

Section: Introductionmentioning

confidence: 99%

Antigen-Induced Reduction in Mast Cell and Basophil Functional Responses due to Reduced Syk Protein Levels

Kepley

2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The high-affinity IgE receptor, FcεRI, is unresponsive on mast cells and basophils from people in several populations through an unknown mechanism. Similarly, FcεRI-positive basophils from ‘nonreleasers’ are IgE-unresponsive and are deficient in the tyrosine kinase Syk. Objective: To test the hypothesis that cross-linking FcεRI on mast cells and basophils leads to FcεRI nonresponsiveness through reduction in Syk protein levels. Methods: Human mast cells and basophils were used to determine if FcεRI hyporesponsiveness correlated with reduced Syk levels. Results: It is shown that suboptimal antigen challenge, that did not lead to significant mediator release, induced nonresponsiveness and correlated with reduced Syk. Other IgE-associated signaling molecules were unaffected by the same treatment. The ability of IgE-unresponsive mast cells to regain FcεRI responsiveness is paralleled by increased cellular Syk levels in vitro. The reduction of Syk levels with suboptimal antigen concentrations was calcium independent and mediated through a proteasome-dependent mechanism. Conclusion: These findings confirm and extend our knowledge about a novel regulatory mechanism for maintaining FcεRI in a quiescent state. This mechanism may also explain why low concentrations of allergen given to patients during allergen immunotherapy induce FcεRI nonresponsiveness and therapeutic benefit without inducing systemic anaphylaxis.

show abstract

“…Several placebo-controlled studies have found significant effects of specific immunotherapy on symptoms, use of medication and allergen-specific and nonspecific hyperresponsiveness in cat- and birch-allergic rhinoconjunctivitis and asthma [1,2,3]. …”

Section: Introductionmentioning

confidence: 99%

Basophil Interleukin 4 and Interleukin 13 Production Is Suppressed during the Early Phase of Rush Immunotherapy

Plewako

Wosińska

Arvidsson

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Studies using rush immunotherapy (RIT) have shown that rapid protection can be achieved using protocols allowing a fast increment of allergen dose. We examined the early effects of RIT on basophil numbers and expression of CD203c, production of interleukin (IL)-4 and IL-13 and histamine release by basophils in the peripheral blood of patients treated with immunotherapy and controls. Methods: Twelve patients treated with RIT and 4 untreated controls were included in the study. Any adverse events were evaluated during the incremental phase of RIT. Mononuclear cells were isolated before the start of RIT and 3 days, 1 week, 4 weeks and 3 months after the beginning of the treatment. Histamine release upon allergen stimulation, expression of CD203c and allergen-induced production of IL-4 and IL-13 by basophils were examined. Results: Significant decreases in blood basophil count (p = 0.02) were observed early in the treatment, returning to baseline values 1 week after the start of RIT. Similarly, histamine release decreased at day 3 (p = 0.02), but returned to pretreatment levels after 1 week. Also, the percentage of IL-4+ and IL-13+ basophils and levels of CD203c expression were markedly reduced early in the treatment. IL-4 and IL-13 production correlated with histamine release and CD203c expression. Histamine release and production of IL-4 and IL-13 by basophils before the treatment correlated with the severity of adverse events during the incremental phase of RIT. Conclusion: We report the decrease in blood basophil numbers, their lower activation status and the reduced production of IL-4 and IL-13 early in the course of RIT. This early suppression of basophil activation could be one mechanism behind the protective effect of RIT.

show abstract

Immunotherapy for cat asthma

Cited by 141 publications

References 21 publications

Immunotherapy as an effective tool in allergy treatment

Immunotherapy as an effective tool in allergy treatment

Antigen-Induced Reduction in Mast Cell and Basophil Functional Responses due to Reduced Syk Protein Levels

Basophil Interleukin 4 and Interleukin 13 Production Is Suppressed during the Early Phase of Rush Immunotherapy

Contact Info

Product

Resources

About